抗血管生成治疗耐药与肿瘤微环境关系的研究进展

Recent advances in the relationship between resistance to tumor antiangiogenic strategies and tumor microenvironment

血管生成对肿瘤的发生、发展及转移起重要作用,抗血管生成治疗成为肿瘤治疗的新靶点,然而抗血管生成治疗存在耐药现象,且在临床中的益处都是短暂的,通常会迅速地出现肿瘤的生长、进展和转移,这与肿瘤微环境的变化密切相关。目前,耐药机制尚未明确,本文主要从其他促血管生成因子或通道、缺氧微环境、细胞自噬、肿瘤基质细胞及其他血管生成方式等方面简述了肿瘤微环境介导抗血管生成治疗耐药的分子机制,以期发现肿瘤血管生成的新靶点,改善抗血管生成治疗的临床效果。

Angiogenesis plays an important role in tumor growth, invasion and metastasis. Development of anti-angiogenic agents opened a new era in cancer therapy. However, the resistance to anti-angiogenic drugs exists, the clinical benefits are transient and the growth, progression, and metastasis of tumors usually occur rapidly, these are closely related to the changes of tumor microenvironment. The mechanisms of resistance are not well understood, the current review introduce the molecular mechanism of tumor microenvironment mediating the resistance to anti-angiogenic drugs from five aspects, such as the other angiogenic factors or channel, hypoxia microenvironment, autophagy, tumor stromal cells and other modes of tumour vascularisation, in order to find a new target of tumor angiogenesis and improve the clinical effect.